Related references
Note: Only part of the references are listed.Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
Carlos H. Barrios et al.
CANCER (2012)
First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
Jonas Bergh et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
Nicholas J. Robert et al.
CLINICAL BREAST CANCER (2011)
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Adam M. Brufsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review
Linda J. M. Oostendorp et al.
LANCET ONCOLOGY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
Carlos H. Barrios et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors
Christopher J. Sweeney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer
Janna Paulsson et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
Sonja Loges et al.
CANCER CELL (2009)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S. George et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
Eva S. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer
H. L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mechanisms of Disease: angiogenesis and the management of breast cancer
Susana Banerjee et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop
S Goswami et al.
CANCER RESEARCH (2005)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation
H Tsuda et al.
CANCER SCIENCE (2005)
Rhebbing up mTOR - New insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis
DJ Kwiatkowski
CANCER BIOLOGY & THERAPY (2003)
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model
LJ Murray et al.
CLINICAL & EXPERIMENTAL METASTASIS (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
G Klement et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
